Valacyclovir Adult Dosing
For adult patients, valacyclovir dosing varies significantly by indication: oral herpes (cold sores) requires 2 grams twice daily for 1 day; genital herpes initial episodes require 1 gram twice daily for 10 days; recurrent genital herpes requires 500 mg twice daily for 3 days; and herpes zoster requires 1 gram three times daily for 7 days, with renal dose adjustments mandatory for creatinine clearance below 50 mL/min. 1
Oral Herpes (Cold Sores/Herpes Labialis)
Standard dosing: 2 grams twice daily for 1 day (12 hours apart) 1
- Initiate at earliest symptom (tingling, itching, burning)
- This single-day regimen is FDA-approved and highly practical for patient adherence
- Available for patients ≥12 years of age
Genital Herpes
First Clinical Episode
Standard dosing: 1 gram twice daily for 10 days 1
- Most effective when started within 48 hours of symptom onset 2
- Alternative from older guidelines: 1 gram twice daily for 7-10 days 2
- Treatment may be extended if healing incomplete after 10 days
Recurrent Episodes
Standard dosing: 500 mg twice daily for 3 days 1
- Initiate at first sign or symptom of recurrence
- Older guideline alternative: 500 mg twice daily for 5 days 2
- Patient should have medication on hand to start immediately at prodrome
Suppressive Therapy (Immunocompetent)
Standard dosing: 1 gram once daily 1
- Alternative for ≤9 recurrences/year: 500 mg once daily 1
- Important caveat: 500 mg once daily is less effective in patients with ≥10 episodes per year 2
- Safety documented for up to 1 year with valacyclovir 2
- Reassess need annually as recurrence frequency naturally decreases over time
Suppressive Therapy (HIV-Infected)
Standard dosing: 500 mg twice daily (for CD4+ ≥100 cells/mm³) 1
- Higher doses may be needed in immunocompromised patients
- Monitor closely for treatment failures
Transmission Reduction
Standard dosing: 500 mg once daily for source partner with ≤9 recurrences/year 1
Herpes Zoster (Shingles)
Standard dosing: 1 gram three times daily for 7 days 1
- Initiate at earliest sign or symptom, ideally within 48 hours of rash onset
- Most effective when started early, though benefit may extend beyond 72 hours 3
- This regimen significantly reduces duration of zoster-associated pain and postherpetic neuralgia compared to acyclovir 4, 3
Renal Dose Adjustments
Dose adjustments are mandatory for creatinine clearance <50 mL/min 1
Cold Sores (Herpes Labialis)
- CrCl 30-49: No reduction (but do not exceed 1 day)
- CrCl 10-29: 1 gram every 24 hours
- CrCl <10: 500 mg every 24 hours
Genital Herpes - Recurrent Episode
- CrCl 30-49: No reduction
- CrCl 10-29: 500 mg every 24 hours
- CrCl <10: 500 mg every 24 hours
Genital Herpes - Suppressive Therapy (Immunocompetent)
- CrCl 30-49: No reduction
- CrCl 10-29: 500 mg every 24 hours
- CrCl <10: 500 mg every 24 hours
For alternate 500 mg daily dose (≤9 recurrences/year):
- CrCl 30-49: No reduction
- CrCl 10-29: 500 mg every 48 hours
- CrCl <10: 500 mg every 48 hours
Genital Herpes - Suppressive Therapy (HIV-Infected)
- CrCl 30-49: No reduction
- CrCl 10-29: 500 mg every 24 hours
- CrCl <10: 500 mg every 24 hours
Herpes Zoster
- CrCl 30-49: 1 gram every 12 hours
- CrCl 10-29: 1 gram every 24 hours
- CrCl <10: 500 mg every 24 hours
Hemodialysis
Administer recommended dose after hemodialysis session 1
- Approximately one-third of acyclovir removed during 4-hour dialysis
- Half-life during hemodialysis: ~4 hours
Peritoneal Dialysis
No supplemental doses required after CAPD or CAVHD 1
Key Clinical Considerations
Timing is critical: Early initiation at prodrome or within 24-48 hours of symptom onset maximizes efficacy across all indications 1, 2
Common pitfall: Failing to adjust doses for renal impairment increases risk of neuropsychiatric adverse effects, though these occur rarely 5. The higher systemic concentrations in renal impairment lead to proportionally higher CSF concentrations, but CSF penetration ratios remain unchanged 5.
Practical advantage: Valacyclovir's superior bioavailability (3-5 times that of acyclovir) allows less frequent dosing, improving adherence while maintaining equivalent or superior efficacy 4, 6, 3, 7
Safety profile: Generally well-tolerated with nausea and headache as most common adverse events; similar tolerability to acyclovir 4, 3, 7